Favipiravir (T-705) protects against Nipah virus infection in the hamster model.

about

Favipiravir (T-705) protects against Nipah virus infection in the hamster model.

Item

http://www.wikidata.org/entity/Q54989893

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Favipiravir (T-705) protects against Nipah virus infection in the hamster model.

@en

type

Item

label

Favipiravir (T-705) protects against Nipah virus infection in the hamster model.

@en

altLabel

Favipiravir (T-705) protects against Nipah virus infection in the hamster model

@en

prefLabel

Favipiravir (T-705) protects against Nipah virus infection in the hamster model.

@en

P1476

Favipiravir (T-705) protects against Nipah virus infection in the hamster model.

@en

P2093

Alexander N Freiberg

http://www.w3.org/2001/XMLSchema#string

Benhur Lee

http://www.w3.org/2001/XMLSchema#string

Birte Kalveram

http://www.w3.org/2001/XMLSchema#string

Jennifer K Smith

http://www.w3.org/2001/XMLSchema#string

Lihong Zhang

http://www.w3.org/2001/XMLSchema#string

Takashi Komeno

http://www.w3.org/2001/XMLSchema#string

Terry Juelich

http://www.w3.org/2001/XMLSchema#string

Yousuke Furuta

http://www.w3.org/2001/XMLSchema#string

P2860

Henipavirus RNA in African bats

Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever

Poly(I)-Poly(C12U) but Not Ribavirin Prevents Death in a Hamster Model of Nipah Virus Infection

Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin

Favipiravir (T-705) inhibits Junín virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic fever

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

A general strategy to endow natural fusion-protein-derived peptides with potent antiviral activity

The pandemic potential of Nipah virus.

Efficient reverse genetics reveals genetic determinants of budding and fusogenic differences between Nipah and Hendra viruses and enables real-time monitoring of viral spread in small animal models of henipavirus infection.

Influenza antivirals currently in late-phase clinical trial.

P304

7604

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-018-25780-3

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Tetsuro Ikegami

Arnold Park

Brian E Dawes

P577

2018-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29765101

http://www.w3.org/2001/XMLSchema#string

P921

Nipah virus

favipiravir

P932

5954062

http://www.w3.org/2001/XMLSchema#string